a public good project by the
Synthesis
Company
of California

© 2026

Robert Wild | doi.page

0 works0 citations0 h-index

Robert Wild

Sensei Biotherapeutics (United States)(US)Tracon Pharmaceuticals (United States)(US)University of Oklahoma Health Sciences Center(US)

Publications by Year

Research Areas

Cancer, Hypoxia, and Metabolism, PI3K/AKT/mTOR signaling in cancer, Cancer Research and Treatments, Autophagy in Disease and Therapy, Adenosine and Purinergic Signaling

Most-Cited Works

→ Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer(2015)302 cited
→ Bacteriophage T7 helicase/primase proteins form rings around single-stranded DNA that suggest a general structure for hexameric helicases.(1995)255 cited
→ Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer(2010)216 cited
→ Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin(2011)200 cited
→ Silvestrol and Episilvestrol, Potential Anticancer Rocaglate Derivatives from Aglaia silvestris(2004)191 cited
→ Novel Strategies for the Discovery of Plant-Derived Anticancer Agents(2003)179 cited

→ Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: Effect on human microvascular endothelial cell proliferation and angiogenesis(1999)147 cited

→ Quantitative Assessment of Angiogenesis and Tumor Vessel Architecture by Computer-Assisted Digital Image Analysis: Effects of VEGF–Toxin Conjugate on Tumor Microvessel Density(2000)135 cited

→ Targeting pancreatic cancer metabolic dependencies through glutamine antagonism(2023)103 cited

Silvestrol, a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in LNCaP cells through the mitochondrial/apoptosome pathway without activation of executioner caspase-3 or -7.(2007)